NCT05999331

Brief Summary

Sepsis, characterized by severe organ dysfunction related to a dysregulated immune response to infection, is often life-threatening in clinical settings. Sepsis can progress to multiple organ dysfunction syndrome (MODS), causing a great risk of mortality. As a vital immune and metabolic organ, liver often suffers damage in this process and often associated with severe adverse consequences. Compared to general sepsis population, sepsis-associated liver dysfunction (SALD) has a higher mortality, up to 68.6%. The aspartate aminotransferase (AST) to platelet (PLT) ratio index (APRI), which can be calculated from conventional laboratory indicators, has long been used in the evaluation of liver damage and fibrosis in patients with hepatitis and nonalcoholic fatty liver disease. AST is a sensitive indicator of early liver function impairment. Additionally, PLT also plays a crucial role in sepsis-induced MODS through regulating inflammation, maintaining tissue integrity, and defending against infection. Study found that APRI was a good predictor of SALD occurrence in pediatric patients with sepsis. Furthermore, APRI has also been used to predict the prognostic in septic patients with no history of chronic liver disease. We conducted a retrospective study based on data from the Medical Information Mart for Intensive Care IV version 2.2 (MIMIC-IV, v2.2) and our own hospital to explore the potential association of APRI with the occurrence of SALD in adult patients with sepsis. Furthermore, we also evaluated the performance of APRI in hypoxic hepatitis and sepsis induced cholestasis (SIC), which are two subtypes of SALD.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
4.6 years until next milestone

First Submitted

Initial submission to the registry

August 11, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 21, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2023

Completed
Last Updated

August 21, 2023

Status Verified

June 1, 2023

Enrollment Period

4.7 years

First QC Date

August 11, 2023

Last Update Submit

August 11, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Occurrence of SALD

    Whether SALD occurs

    30 days after ICU admission

Secondary Outcomes (1)

  • mortality

    30 days after ICU admission

Study Arms (2)

Non-SALD group

SALD did not occur in adult patients with sepsis during ICU stay.SALD was diagnosed by the following criteria: (1) ALT or AST≥20 folds upper limit of normal level; or (2) TBIL≥2.0 mg/dL.

Other: initial aspartate aminotransferase (AST) to platelet (PLT) ratio index

SALD group

SALD was occured in adult patients with sepsis during ICU stay.SALD was diagnosed by the following criteria: (1) ALT or AST≥20 folds upper limit of normal level; or (2) TBIL≥2.0 mg/dL. SALD is further divided into hypoxic hepatitis and sepsis induced cholestasis (SIC), based on the presence or absence of elevated TBIL. Hypoxic hepatitis is diagnosed when elevated transaminase (\>800 IU/L) is present only; and SIC is diagnosed when TBIL is elevated (≥2.0 mg/dL).

Other: initial aspartate aminotransferase (AST) to platelet (PLT) ratio index

Interventions

All eligible patients were given antibiotics therapy, actively control infection source, as well as other supportive therapy to maintain organ function.

Non-SALD groupSALD group

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Briefly, patients with confirmed or suspected foci of infectious and a concurrent SOFA≥2 were diagnosed with sepsis. SALD was diagnosed by the following criteria: (1) ALT or AST≥20 folds upper limit of normal level; or (2) TBIL≥2.0 mg/dL.

You may qualify if:

  • adult sepsis patients (≥18 years)

You may not qualify if:

  • all types of chronic liver disease;
  • viral hepatitis;
  • primary acute cholangiopathies;
  • cholecystitis;
  • hepatic infarction;
  • liver necrosis;
  • liver trauma;
  • length of ICU stay \< 24 hours;
  • Patients without simultaneous AST and PLT data in the first 24 hours after ICU admission.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of General Surgery of Jinling Hospital

Nanjing, Jiangsu, 210002, China

RECRUITING

Related Publications (2)

  • Dou J, Zhou Y, Cui Y, Chen M, Wang C, Zhang Y. AST-to-Platelet Ratio Index as Potential Early-Warning Biomarker for Sepsis-Associated Liver Injury in Children: A Database Study. Front Pediatr. 2019 Aug 21;7:331. doi: 10.3389/fped.2019.00331. eCollection 2019.

    PMID: 31497584BACKGROUND
  • Zhu X, Hu X, Qin X, Pan J, Zhou W. An elevated Fibrosis-4 score is associated with poor clinical outcomes in patients with sepsis: an observational cohort study. Pol Arch Intern Med. 2020 Dec 22;130(12):1064-1073. doi: 10.20452/pamw.15699. Epub 2020 Dec 4.

    PMID: 33274619BACKGROUND

MeSH Terms

Conditions

Liver Diseases

Condition Hierarchy (Ancestors)

Digestive System Diseases

Study Officials

  • Wenkui Yu, professor

    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    STUDY CHAIR

Central Study Contacts

Beiyuan Zhang, M.S.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
30 Days
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 11, 2023

First Posted

August 21, 2023

Study Start

January 1, 2019

Primary Completion

September 30, 2023

Study Completion

September 30, 2023

Last Updated

August 21, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

The research is not over yet

Locations